Dianthus Therapeutics (DNTH) Institutional Ownership → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free DNTH Stock Alerts $26.50 -1.19 (-4.30%) (As of 01:27 PM ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Dianthus Therapeutics (NASDAQ:DNTH)CurrentInstitutional OwnershipPercentage47.53%Number ofInstitutional Buyers(last 12 months)13TotalInstitutional Inflows(last 12 months)$156.48MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$1.92M Get DNTH Insider Trade Alerts Want to know when executives and insiders are buying or selling Dianthus Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data DNTH Institutional Buying and Selling by Quarter Ad Weiss RatingsThis is the best new way to score with AIIf you thought that you missed your chance to score big on AI, I have great news. A rare second profit window is starting to open.Click now for the best way into the newest AI projects Dianthus Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/16/2024Bain Capital Life Sciences Investors LLC2,992,028$89.76M7.2%N/A10.194% 5/14/2024 StemPoint Capital LP43,456$1.30M0.3%N/A0.148% 5/10/2024 Acadian Asset Management LLC4,012$120K0.0%-77.6%0.014% 5/10/2024 Vanguard Group Inc.537,828$16.14M0.0%+250.0%1.833% 5/6/2024 Atlas Venture Life Science Advisors LLC186,979$5.61M0.5%-21.1%0.637% 5/2/2024 Hussman Strategic Advisors Inc.21,000$630K0.1%N/A0.072% 2/15/2024Octagon Capital Advisors LP554,000$5.76M0.9%+15.4%3.738% 2/14/2024 Vestal Point Capital LP135,000$1.40M0.1%N/A0.911% 2/13/2024Tower Research Capital LLC TRC 2,430$25K0.0%N/A0.016% 12/6/2023 Citigroup Inc.3,868$53K0.0%N/A0.026% 11/15/2023Laurion Capital Management LP36,393$497K0.0%N/A0.960% 11/14/2023Avidity Partners Management LP1,217,554$16.64M0.7%N/A32.125% 11/13/2023 Atlas Venture Life Science Advisors LLC236,979$3.24M0.5%N/A6.249% 11/13/2023 Acadian Asset Management LLC22,299$303K0.0%N/A0.588% 11/13/2023 FMR LLC2,218,212$28.96M0.0%N/A58.497% (Data available from 1/1/2016 forward) DNTH Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of DNTH shares? During the previous two years, 13 institutional investors and hedge funds held shares of Dianthus Therapeutics. The most heavily invested institutionals were Bain Capital Life Sciences Investors LLC ($89.76M), FMR LLC ($28.96M), Avidity Partners Management LP ($16.64M), Vanguard Group Inc. ($16.14M), Octagon Capital Advisors LP ($5.76M), Atlas Venture Life Science Advisors LLC ($5.61M), and Vestal Point Capital LP ($1.40M).Learn more on DNTH's institutional investors. What percentage of Dianthus Therapeutics stock is owned by institutional investors? 47.53% of Dianthus Therapeutics stock is owned by institutional investors. Learn more on DNTH's institutional investor holdings. Which institutional investors have been buying Dianthus Therapeutics stock? Of the 13 institutional investors that purchased Dianthus Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Bain Capital Life Sciences Investors LLC ($2.99M), FMR LLC ($2.22M), Avidity Partners Management LP ($1.22M), Vanguard Group Inc. ($384.18K), Atlas Venture Life Science Advisors LLC ($236.98K), Vestal Point Capital LP ($135K), and Octagon Capital Advisors LP ($74K). How much institutional buying is happening at Dianthus Therapeutics? Institutional investors have bought a total of 7,387,401 shares in the last 24 months. This purchase volume represents approximately $156.48M in transactions. Which Dianthus Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Dianthus Therapeutics stock in the last 24 months: Atlas Venture Life Science Advisors LLC ($50K), and Acadian Asset Management LLC ($13.88K). How much institutional selling is happening at Dianthus Therapeutics? Institutional investors have sold a total of 63,876 shares in the last 24 months. This volume of shares sold represents approximately $1.92M in transactions. Related Companies: Tango Therapeutics Major Shareholders Zentalis Pharmaceuticals Major Shareholders Arcturus Therapeutics Major Shareholders Evolus Major Shareholders Longboard Pharmaceuticals Major Shareholders ALX Oncology Major Shareholders Pliant Therapeutics Major Shareholders Disc Medicine Major Shareholders Praxis Precision Medicines Major Shareholders ARS Pharmaceuticals Major Shareholders This page (NASDAQ:DNTH) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon’s New Device is About to Shock the WorldInvestorPlaceGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
